Loading…

The epitope recognized by rituximab

Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CAL...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2006-09, Vol.108 (6), p.1975-1978
Main Authors: Binder, Mascha, Otto, Florian, Mertelsmann, Roland, Veelken, Hendrik, Trepel, Martin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83
cites cdi_FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83
container_end_page 1978
container_issue 6
container_start_page 1975
container_title Blood
container_volume 108
creator Binder, Mascha
Otto, Florian
Mertelsmann, Roland
Veelken, Hendrik
Trepel, Martin
description Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CALMIANSC) is related to (170)ANPS(173) within CD20, while another motif (WEWTI) may mimic the CD20 segment (182)YCYSI(185). Phages displaying either motif specifically bound rituximab. Binding to rituximab by the CD20 peptides ANPS and YCYSI was weak when used separately and enhanced when both peptides were linked. Recombinant CD20 extracellular loop proteins blocked binding of the selected CWWEWTIGC phage to rituximab, suggesting that CWWEWTIGC mimics the epitope. Blocking capacity was strongly reduced upon mutation of the CD20 strings ANPS or YCYSI. We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183).
doi_str_mv 10.1182/blood-2006-04-014639
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68835985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120525743</els_id><sourcerecordid>68835985</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83</originalsourceid><addsrcrecordid>eNp9kE1LxDAURYMozjj6D0QKorvqS9o06UaQwS8YcDOuQ5q-aKTT1qQjjr_e1hbcuXqLd-7lcgg5pXBFqWTXRdU0ZcwAshjSGGiaJfkemVPOZAzAYJ_MYXimuaAzchTCO_RQwvghmdFMAAeZzcn5-g0jbF3XtBh5NM1r7b6xjIpd5F23_XIbXRyTA6urgCfTXZCX-7v18jFePT88LW9XseHAuphKKkopLGW5zERueJEKSTnnZZlzluZWawZGSEiESai1wmhNOQrbj2WAMlmQy7G39c3HFkOnNi4YrCpdY7MNKpMy4bnkPZiOoPFNCB6tan0_1O8UBTXIUb9y1CBHQapGOX3sbOrfFhss_0KTjR64mAAdjK6s17Vx4Y-TFATIoehm5LC38enQq2Ac1gZL1yvsVNm4_5f8AISKgE8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68835985</pqid></control><display><type>article</type><title>The epitope recognized by rituximab</title><source>ScienceDirect Journals</source><creator>Binder, Mascha ; Otto, Florian ; Mertelsmann, Roland ; Veelken, Hendrik ; Trepel, Martin</creator><creatorcontrib>Binder, Mascha ; Otto, Florian ; Mertelsmann, Roland ; Veelken, Hendrik ; Trepel, Martin</creatorcontrib><description>Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CALMIANSC) is related to (170)ANPS(173) within CD20, while another motif (WEWTI) may mimic the CD20 segment (182)YCYSI(185). Phages displaying either motif specifically bound rituximab. Binding to rituximab by the CD20 peptides ANPS and YCYSI was weak when used separately and enhanced when both peptides were linked. Recombinant CD20 extracellular loop proteins blocked binding of the selected CWWEWTIGC phage to rituximab, suggesting that CWWEWTIGC mimics the epitope. Blocking capacity was strongly reduced upon mutation of the CD20 strings ANPS or YCYSI. We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183).</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2006-04-014639</identifier><identifier>PMID: 16705086</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Amino Acid Sequence ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal, Murine-Derived ; Antigens, CD20 - chemistry ; Antigens, CD20 - genetics ; Antineoplastic agents ; B-Lymphocytes - immunology ; Binding Sites ; Biological and medical sciences ; Epitopes - chemistry ; Epitopes - genetics ; Hematologic and hematopoietic diseases ; Humans ; Immunotherapy ; In Vitro Techniques ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Molecular Sequence Data ; Peptide Library ; Pharmacology. Drug treatments ; Protein Structure, Tertiary ; Recombinant Fusion Proteins - chemistry ; Recombinant Fusion Proteins - genetics ; Recombinant Fusion Proteins - immunology ; Rituximab</subject><ispartof>Blood, 2006-09, Vol.108 (6), p.1975-1978</ispartof><rights>2006 American Society of Hematology</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83</citedby><cites>FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120525743$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18107089$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16705086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Binder, Mascha</creatorcontrib><creatorcontrib>Otto, Florian</creatorcontrib><creatorcontrib>Mertelsmann, Roland</creatorcontrib><creatorcontrib>Veelken, Hendrik</creatorcontrib><creatorcontrib>Trepel, Martin</creatorcontrib><title>The epitope recognized by rituximab</title><title>Blood</title><addtitle>Blood</addtitle><description>Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CALMIANSC) is related to (170)ANPS(173) within CD20, while another motif (WEWTI) may mimic the CD20 segment (182)YCYSI(185). Phages displaying either motif specifically bound rituximab. Binding to rituximab by the CD20 peptides ANPS and YCYSI was weak when used separately and enhanced when both peptides were linked. Recombinant CD20 extracellular loop proteins blocked binding of the selected CWWEWTIGC phage to rituximab, suggesting that CWWEWTIGC mimics the epitope. Blocking capacity was strongly reduced upon mutation of the CD20 strings ANPS or YCYSI. We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183).</description><subject>Amino Acid Sequence</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antigens, CD20 - chemistry</subject><subject>Antigens, CD20 - genetics</subject><subject>Antineoplastic agents</subject><subject>B-Lymphocytes - immunology</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Epitopes - chemistry</subject><subject>Epitopes - genetics</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>In Vitro Techniques</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Molecular Sequence Data</subject><subject>Peptide Library</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Structure, Tertiary</subject><subject>Recombinant Fusion Proteins - chemistry</subject><subject>Recombinant Fusion Proteins - genetics</subject><subject>Recombinant Fusion Proteins - immunology</subject><subject>Rituximab</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAURYMozjj6D0QKorvqS9o06UaQwS8YcDOuQ5q-aKTT1qQjjr_e1hbcuXqLd-7lcgg5pXBFqWTXRdU0ZcwAshjSGGiaJfkemVPOZAzAYJ_MYXimuaAzchTCO_RQwvghmdFMAAeZzcn5-g0jbF3XtBh5NM1r7b6xjIpd5F23_XIbXRyTA6urgCfTXZCX-7v18jFePT88LW9XseHAuphKKkopLGW5zERueJEKSTnnZZlzluZWawZGSEiESai1wmhNOQrbj2WAMlmQy7G39c3HFkOnNi4YrCpdY7MNKpMy4bnkPZiOoPFNCB6tan0_1O8UBTXIUb9y1CBHQapGOX3sbOrfFhss_0KTjR64mAAdjK6s17Vx4Y-TFATIoehm5LC38enQq2Ac1gZL1yvsVNm4_5f8AISKgE8</recordid><startdate>20060915</startdate><enddate>20060915</enddate><creator>Binder, Mascha</creator><creator>Otto, Florian</creator><creator>Mertelsmann, Roland</creator><creator>Veelken, Hendrik</creator><creator>Trepel, Martin</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060915</creationdate><title>The epitope recognized by rituximab</title><author>Binder, Mascha ; Otto, Florian ; Mertelsmann, Roland ; Veelken, Hendrik ; Trepel, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Amino Acid Sequence</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antigens, CD20 - chemistry</topic><topic>Antigens, CD20 - genetics</topic><topic>Antineoplastic agents</topic><topic>B-Lymphocytes - immunology</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Epitopes - chemistry</topic><topic>Epitopes - genetics</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>In Vitro Techniques</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Molecular Sequence Data</topic><topic>Peptide Library</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Structure, Tertiary</topic><topic>Recombinant Fusion Proteins - chemistry</topic><topic>Recombinant Fusion Proteins - genetics</topic><topic>Recombinant Fusion Proteins - immunology</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Binder, Mascha</creatorcontrib><creatorcontrib>Otto, Florian</creatorcontrib><creatorcontrib>Mertelsmann, Roland</creatorcontrib><creatorcontrib>Veelken, Hendrik</creatorcontrib><creatorcontrib>Trepel, Martin</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Binder, Mascha</au><au>Otto, Florian</au><au>Mertelsmann, Roland</au><au>Veelken, Hendrik</au><au>Trepel, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The epitope recognized by rituximab</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2006-09-15</date><risdate>2006</risdate><volume>108</volume><issue>6</issue><spage>1975</spage><epage>1978</epage><pages>1975-1978</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Rituximab is a monoclonal antibody widely used in the treatment of malignant lymphoma and autoimmunity. Its epitope within the B-cell antigen CD20 is largely unknown. We used phage display libraries to select peptides binding to rituximab. Enriched peptides showed 2 sequence patterns: one motif (CALMIANSC) is related to (170)ANPS(173) within CD20, while another motif (WEWTI) may mimic the CD20 segment (182)YCYSI(185). Phages displaying either motif specifically bound rituximab. Binding to rituximab by the CD20 peptides ANPS and YCYSI was weak when used separately and enhanced when both peptides were linked. Recombinant CD20 extracellular loop proteins blocked binding of the selected CWWEWTIGC phage to rituximab, suggesting that CWWEWTIGC mimics the epitope. Blocking capacity was strongly reduced upon mutation of the CD20 strings ANPS or YCYSI. We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183).</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>16705086</pmid><doi>10.1182/blood-2006-04-014639</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2006-09, Vol.108 (6), p.1975-1978
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_68835985
source ScienceDirect Journals
subjects Amino Acid Sequence
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 - chemistry
Antigens, CD20 - genetics
Antineoplastic agents
B-Lymphocytes - immunology
Binding Sites
Biological and medical sciences
Epitopes - chemistry
Epitopes - genetics
Hematologic and hematopoietic diseases
Humans
Immunotherapy
In Vitro Techniques
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Molecular Sequence Data
Peptide Library
Pharmacology. Drug treatments
Protein Structure, Tertiary
Recombinant Fusion Proteins - chemistry
Recombinant Fusion Proteins - genetics
Recombinant Fusion Proteins - immunology
Rituximab
title The epitope recognized by rituximab
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A08%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20epitope%20recognized%20by%20rituximab&rft.jtitle=Blood&rft.au=Binder,%20Mascha&rft.date=2006-09-15&rft.volume=108&rft.issue=6&rft.spage=1975&rft.epage=1978&rft.pages=1975-1978&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2006-04-014639&rft_dat=%3Cproquest_cross%3E68835985%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c502t-1817d87f1298679c5b4781555dd95249faa20c78037c31ff7caa15e7f02020e83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68835985&rft_id=info:pmid/16705086&rfr_iscdi=true